CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Pharvaris N.V. (PHVS) / deucrictibant
Forward catalyst · PHVS

deucrictibant

Sponsor Pharvaris N.V. · listed as PHVS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

deucrictibant is a clinical-stage drug asset sponsored by Pharvaris N.V., listed as PHVS. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Aug 2026 (month precision, medium confidence), tied to trial NCT06669754. The asset is in Phase 3 and currently active not recruiting, studied in Hereditary Angioedema (HAE). It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-08-31
As disclosedAug 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06669754
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorPharvaris Netherlands B.V.
Listed asPHVS
Condition(s)Hereditary Angioedema (HAE)

All tracked catalysts for deucrictibant

DateEventConfidenceTrial
2026-08-31READOUTmediumNCT06669754
2027-06-30READOUTmediumNCT05396105
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More PHVS catalysts